Analyses / Whip Count Analysis / 119 · HR 1262 Whip Count Analysis

119-HR-1262 DC Insider Whip Count Analysis

119 · HR 1262 Mikaela Naylon Give Kids a Chance Act

health_and_safety Health
Give Kids a Chance Act of 2025This bill expands the Food and Drug Administration’s (FDA’s) authority with respect to research on rare pediatric diseases, including by permitting the FDA to take...

H.R. 1262 cleared the House on Dec. 1 by voice vote after a 47–0 E&C markup and 300+ cosponsors; it was received in the Senate on Dec. 2. With Republicans holding the Senate and HELP Chair Bill Cassidy supportive of the bill’s core orphan‑exclusivity fix, the path is a quick hotline/UC if no holds surface. The only real risk is a UC objection aimed at Section 6 (orphan exclusivity) or fee/office provisions; otherwise passage probability is high in the lame December window or early January. [1]Library of Congress — Congress.gov – H.R. 1262 Actions (119th Congress)[2]Library of Congress — Congress.gov – H.R. 1262 overview (cosponsors, summary)[3]U.S. Senate — Senate.gov – Party Division, 119th Congress[4]Office of Sen. Bill Cassidy — Cassidy-Baldwin press release on RARE Act (orphan…

Analyzed as
DC Insider
Published
03 Dec 2025
Updated
03 Dec 2025
Tags
whip count · health policy · FDA
Unvetted
01 · Section

Breakdown: expected support/opposition

Bottom line: this is a bipartisan pediatric/rare‑disease package with overwhelming House support and natural Senate HELP jurisdiction; absent a hold, expect near‑unanimous Senate passage by unanimous consent. [1]Library of Congress — Congress.gov – H.R. 1262 Actions (119th Congress)[5]U.S. Senate HELP Committee — Senate HELP Committee – Jurisdiction (FDA/NIH/HHS)

  • House posture: Passed under suspension by voice vote on Dec. 1 after a 47–0 Energy & Commerce markup; 313 cosponsors at passage. That signals broad, cross‑caucus buy‑in. [1]Library of Congress — Congress.gov – H.R. 1262 Actions (119th Congress)[6]Web search · turn 3 #0[2]Library of Congress — Congress.gov – H.R. 1262 overview (cosponsors, summary)
  • Senate control/context: GOP majority; John Thune as Majority Leader has emphasized keeping the 60‑vote Senate, but this kind of non‑controversial health bill typically moves by UC rather than cloture. [3]U.S. Senate — Senate.gov – Party Division, 119th Congress[7]Office of Sen. John Thune — Thune delivers first remarks as Senate Majority Lea…
  • Committee of referral: Upon receipt, the bill’s FDA/NIH/OPTN provisions place it squarely in Senate HELP’s jurisdiction (HELP oversees FDA/NIH). Expect HELP staff to clear text; a formal markup is unlikely if UC is the chosen path. [1]Library of Congress — Congress.gov – H.R. 1262 Actions (119th Congress)[5]U.S. Senate HELP Committee — Senate HELP Committee – Jurisdiction (FDA/NIH/HHS)
  • Issue coalitions: Patient/rare‑disease groups (ACS CAN, NORD, Foundation Fighting Blindness, Kids v Cancer) are publicly supportive, reinforcing bipartisan cover. Organized industry opposition is not prominent publicly, but some manufacturers have flagged risk around narrowing orphan exclusivity in SEC filings—an indicator of potential pharma lobbying against Section 6. [8]ACS CAN — ACS CAN – Community Support Letter for Give Kids A Chance[4]Office of Sen. Bill Cassidy — Cassidy-Baldwin press release on RARE Act (orphan…[9]PR Newswire — Foundation Fighting Blindness – PR urging advancement of H.R. 126…[10]Kids v Cancer — Kids v Cancer – GKCA overview/advocacy[11]U.S. SEC EDGAR — SEC filing example noting legislative risk on orphan exclusivi…
  • Floor timing: December floor is crowded (e.g., NDAA), but UC bills can be cleared between larger items; Senate received H.R. 1262 on Dec. 2. [12]Axios — Axios – Stefanik–Johnson feud adds friction during NDAA week[1]Library of Congress — Congress.gov – H.R. 1262 Actions (119th Congress)
House E&C markup vote
470 (unanimous)
House cosponsors at passage
313members
House floor
1Voice vote under suspension (Dec. 1)
Senate majority
53R seats (119th)
02 · Section

Key legislators and pivotal votes

No formal Senate whip count yet; success hinges on leadership floor time and clearing UC holds in the GOP conference.

  • Bill Cassidy (R‑LA), HELP Chair: Controls committee clearance and is an on‑record backer of codifying FDA’s indication‑level orphan exclusivity (the bill’s Section 6 approach). His support materially reduces intra‑GOP policy friction. [13]U.S. Senate HELP Committee GOP — HELP Republicans – Notice of organizing sessio…[4]Office of Sen. Bill Cassidy — Cassidy-Baldwin press release on RARE Act (orphan…
  • John Thune (R‑SD), Majority Leader: Gatekeeper for hotline/UC. His preference to preserve the 60‑vote Senate points toward UC for consensus bills; leadership can slot this between NDAA actions. [7]Office of Sen. John Thune — Thune delivers first remarks as Senate Majority Lea…
  • Chuck Schumer (D‑NY), Minority Leader: Likely to cooperate on UC; Democrats have long backed pediatric cancer/rare‑disease measures. No contrary public signals. [14]Web search · turn 11 #14
  • Markwayne Mullin (R‑OK) & Michael Bennet (D‑CO), Senate leads on the companion: Bipartisan sponsors expected to run the hotline and resolve any hold‑level concerns. [15]Office of Sen. Markwayne Mullin — Mullin–Bennet introduce Give Kids a Chance Ac…
  • House leads/validators: Buddy Carter managed the suspension; E&C Chair Brett Guthrie lauded passage—signals that House Republicans (including leadership) are aligned if a Senate‑tweaked bill needs a quick House concurrence. [1]Library of Congress — Congress.gov – H.R. 1262 Actions (119th Congress)[16]House E&C Committee — House Energy & Commerce – Chair Guthrie statement on Hous…
  • Potential UC risks: Senators known to force debates on new authorities/fees or on pharma policy (e.g., historical UC objections from fiscal conservatives) could ask to modify Section 6 or delay UC; that would force time‑consuming cloture the week of NDAA. [17]Web search · turn 15 #12
03 · Section

Leadership stance and procedural dynamics

Leadership and committees have the leverage to move this quickly if they choose; the only meaningful obstacle is a single‑member UC hold.

  • House leadership: Allowing suspension time and clearing it by voice vote reflects tacit leadership support; E&C Republicans are publicly touting the bill. [1]Library of Congress — Congress.gov – H.R. 1262 Actions (119th Congress)[16]House E&C Committee — House Energy & Commerce – Chair Guthrie statement on Hous…
  • Senate leadership: GOP majority with Thune; filibuster retained. For non‑controversial health items, the standard play is hotline/UC. If a hold appears, leaders must either negotiate narrow edits (most likely around Section 6) or burn floor for cloture—which is unlikely in December. [3]U.S. Senate — Senate.gov – Party Division, 119th Congress[7]Office of Sen. John Thune — Thune delivers first remarks as Senate Majority Lea…
  • Committee leverage: HELP staff can vet the House text quickly; Cassidy has already advanced the same orphan‑exclusivity policy with bipartisan validators (and NORD support), lowering intra‑committee risk. [4]Office of Sen. Bill Cassidy — Cassidy-Baldwin press release on RARE Act (orphan…
  • Calendar reality: As NDAA nears the floor, leadership often batches small bipartisan bills for UC clearance; the House’s early‑December action positions H.R. 1262 for that window. [12]Axios — Axios – Stefanik–Johnson feud adds friction during NDAA week
04 · Section

Assessment: whip count and odds

Given coalition breadth and process options, this is positioned to pass quickly unless a targeted policy dispute forces time.

  • Expected Senate vote method: Unanimous consent after hotline. If UC is blocked, leaders likely defer to early January rather than spend cloture time in mid‑December. [3]U.S. Senate — Senate.gov – Party Division, 119th Congress
  • Policy friction point: Section 6 (orphan‑drug exclusivity “approved use or indication”) is the only piece with potential organized pushback; however, HELP Chair Cassidy has already fronted this fix with bipartisan and patient‑group backing, which blunts opposition. [4]Office of Sen. Bill Cassidy — Cassidy-Baldwin press release on RARE Act (orphan…
  • Interest‑group landscape: Patient/rare‑disease groups strongly supportive; pharma filings acknowledge risk from a legislative fix—suggesting some industry lobbying, but no visible public campaign to kill the bill. [8]ACS CAN — ACS CAN – Community Support Letter for Give Kids A Chance[9]PR Newswire — Foundation Fighting Blindness – PR urging advancement of H.R. 126…[11]U.S. SEC EDGAR — SEC filing example noting legislative risk on orphan exclusivi…
  • Institutional context: FDA/NIH/OPTN issues are squarely HELP; no budget point‐of‐order risk is apparent given PRV fee structure and absence of costly mandates in the House narrative. [5]U.S. Senate HELP Committee — Senate HELP Committee – Jurisdiction (FDA/NIH/HHS)
05 · Section

Core sourcing (selected)

Key public records and leadership/committee sources underpin the analysis.

  • Congress.gov bill history: House passage by voice; received in Senate Dec. 2; 47–0 E&C vote; 313 cosponsors. [1]Library of Congress — Congress.gov – H.R. 1262 Actions (119th Congress)[2]Library of Congress — Congress.gov – H.R. 1262 overview (cosponsors, summary)
  • Senate party division and leadership posture. [3]U.S. Senate — Senate.gov – Party Division, 119th Congress[7]Office of Sen. John Thune — Thune delivers first remarks as Senate Majority Lea…
  • HELP jurisdiction over FDA/NIH; Cassidy’s public stance on orphan‑exclusivity fix with NORD backing. [5]U.S. Senate HELP Committee — Senate HELP Committee – Jurisdiction (FDA/NIH/HHS)[4]Office of Sen. Bill Cassidy — Cassidy-Baldwin press release on RARE Act (orphan…
  • Patient/advocacy endorsements (ACS CAN, Foundation Fighting Blindness, Kids v Cancer); Senate companion sponsors’ release. [8]ACS CAN — ACS CAN – Community Support Letter for Give Kids A Chance[9]PR Newswire — Foundation Fighting Blindness – PR urging advancement of H.R. 126…[10]Kids v Cancer — Kids v Cancer – GKCA overview/advocacy[15]Office of Sen. Markwayne Mullin — Mullin–Bennet introduce Give Kids a Chance Ac…
  • Floor‑time context (NDAA week) affecting UC windows. [12]Axios — Axios – Stefanik–Johnson feud adds friction during NDAA week
Sources cited
  1. [1] Congress.gov – H.R. 1262 Actions (119th Congress) Library of Congress
  2. [2] Congress.gov – H.R. 1262 overview (cosponsors, summary) Library of Congress
  3. [3] Senate.gov – Party Division, 119th Congress U.S. Senate
  4. [4] Cassidy-Baldwin press release on RARE Act (orphan exclusivity fix) with NORD support Office of Sen. Bill Cassidy
  5. [5] Senate HELP Committee – Jurisdiction (FDA/NIH/HHS) U.S. Senate HELP Committee
  6. [6] Web search · turn 3 #0
  7. [7] Thune delivers first remarks as Senate Majority Leader Office of Sen. John Thune
  8. [8] ACS CAN – Community Support Letter for Give Kids A Chance ACS CAN
  9. [9] Foundation Fighting Blindness – PR urging advancement of H.R. 1262 (PRV) PR Newswire
  10. [10] Kids v Cancer – GKCA overview/advocacy Kids v Cancer
  11. [11] SEC filing example noting legislative risk on orphan exclusivity (industry sensitivity) U.S. SEC EDGAR
  12. [12] Axios – Stefanik–Johnson feud adds friction during NDAA week Axios
  13. [13] HELP Republicans – Notice of organizing session (confirms Cassidy as chair) U.S. Senate HELP Committee GOP
  14. [14] Web search · turn 11 #14
  15. [15] Mullin–Bennet introduce Give Kids a Chance Act (Senate companion) Office of Sen. Markwayne Mullin
  16. [16] House Energy & Commerce – Chair Guthrie statement on House passage of H.R. 1262 House E&C Committee
  17. [17] Web search · turn 15 #12

Discussion